Clinical Trial Update: Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Envollizumab with Fruquintinib and SOX vs SOX for conversion therapy in advanced gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Envollizumab (null)
• Fruquintinib (fruquintinib)
• SOX (SOX)

Snippet

Sponsor: Fujian Medical University | Conditions: Gastric Cancer | Phase 3 | Status: NOT_YET_RECRUITING